Shares of BAO PHARMA-B (02659) surged more than 6% in early trading. At the time of writing, the stock is up 2.76%, trading at HK$20.10 with a turnover of HK$7.1887 million.

In late June, the company announced that the clinical trial application for its self-developed BJ044 injection (recombinant ulinastatin) was officially approved by the National Medical Products Administration. BJ044 is the world's first recombinant ulinastatin product developed using synthetic biology technology. With comprehensive advantages in purity, safety, consistency, and cost-effectiveness, BJ044 is expected to systematically replace existing urine-extracted products.

Pipeline Synergy and Strategic Differentiation

It is noteworthy that this product forms pipeline synergy with the company's other recombinant protease, KJ101. Together, they validate the company's technological platform capability for "recombinant replacement of traditional biochemical extraction." Leveraging multiple expression systems such as CHO and yeast, the company possesses the replicable capability to continuously transform traditional extraction-based drugs. This approach builds a differentiated recombinant protein innovation pipeline, setting it apart from the homogenized research and development routes in the industry that are crowded with monoclonal antibodies and ADCs.